A 28-year-old woman from Delhi presents with a 3-year history of irregular menstrual cycles (ranging from 35 to 90 days) and progressive hirsutism on the face and abdomen. She has gained 8 kg over the past 2 years despite no change in diet. On examination, BMI is 28 kg/m², acne is present on the face, and clitoromegaly is absent. Pelvic ultrasound shows multiple small follicles (8–10 mm) arranged peripherally in both ovaries with increased stromal echogenicity. Fasting blood glucose is 92 mg/dL, and serum testosterone is 0.8 ng/mL (normal <0.7 ng/mL). LH:FSH ratio is 3.2:1. What is the most appropriate first-line pharmacological management?

Explanation

## Diagnosis: PCOD (Polycystic Ovary Disease) This patient meets Rotterdam criteria for PCOD: - **Oligomenorrhoea** (irregular cycles >35 days) - **Clinical hyperandrogenism** (hirsutism, acne) - **Polycystic ovarian morphology** on ultrasound (≥12 follicles per ovary, increased stroma) - **Biochemical hyperandrogenism** (elevated testosterone) - **Elevated LH:FSH ratio** (normally 1:1, here 3.2:1) ## First-Line Management Strategy **Key Point:** First-line therapy in PCOD combines metabolic and hormonal management, especially in women seeking cycle regulation and contraception. ### Rationale for Combined Oral Contraceptive (COC) + Metformin | Component | Role | Evidence | |-----------|------|----------| | **COC** | Suppresses LH → ↓ ovarian androgen production; regulates menstrual cycles; provides contraception | First-line for cycle regulation and hyperandrogenism | | **Metformin** | Improves insulin sensitivity; reduces hyperinsulinaemia; aids weight loss; prevents T2DM progression | Addresses metabolic dysfunction; improves ovulation rates | **High-Yield:** Metformin 500 mg TDS is the standard insulin-sensitizing agent in PCOD. It is particularly beneficial in: - Obese PCOD patients (BMI >25) - Those with impaired fasting glucose or insulin resistance - Women planning pregnancy (improves ovulation) **Clinical Pearl:** The combination of COC + metformin addresses BOTH the reproductive (irregular cycles, hyperandrogenism) and metabolic (insulin resistance, weight gain) components of PCOD. ## Why This Patient Needs Both Agents 1. **COC alone** would regulate cycles and suppress androgens but does NOT address insulin resistance → continued weight gain and metabolic risk. 2. **Metformin alone** would improve insulin sensitivity but would NOT regulate cycles or suppress androgens rapidly. 3. **Combined approach** is synergistic: COC provides rapid symptom relief; metformin prevents long-term metabolic complications (T2DM, cardiovascular disease). **Mnemonic:** **PCOD First-Line = COC + Met** (Combined Oral Contraceptive + Metformin) ## Lifestyle Modifications (Concurrent) - Weight loss of 5–10% improves insulin sensitivity and ovulation rates - Regular aerobic exercise - Dietary modification (low glycaemic index) [cite:Textbook of Obstetrics and Gynaecology by Jeffcoate 3e, ASRM PCOD Guidelines 2018]